Cystic Fibrosis Foundation CEO salary and executive pay
Cystic Fibrosis Foundation paid its CEO, Michael P Boyle MD, $1,275,151 for the fiscal year ending December 2024. That is down $197,631 (13.4%) from the fiscal year ending December 2023. Total revenue on that return was $355,798,320, up 21.8% from $292,016,280 for the fiscal year ending December 2023. Cystic Fibrosis Foundation ranks 9th of 11 disease charities and medical research groups on this site by CEO pay. Cystic Fibrosis Foundation has 3 Form 990 returns on record, for fiscal years ending 2022 to 2024.
Last updated from IRS e-file data. EIN 13-1930701, Bethesda, MD.
CEO, fiscal year ending December 2024
$1,275,151
Highest-paid person, fiscal year ending December 2024
$1,942,627John C Mahler Jr MDCHIEF INVESTMENT OFFICER
- Total revenue
- $355,798,320
- CEO pay vs. peers
- Higher than 45%
Source: Form 990, fiscal year ending December 2024, IRS object ID 202533189349311948.View the filing
Peers: the 207 other organizations on this site with revenue of $50 million to $500 million. Ranked 114th of 208 by top pay as a share of revenue. Pay is 0.36% of revenue, our calculation from the same return. Revenue is Part I, line 12; peers are compared on their latest full-year returns.
Highest-paid people on the latest return
On the latest return, 13 people were paid more than $500,000, 5 of them more than $1 million.
| Name and title | Total |
|---|---|
| John C Mahler Jr MDCHIEF INVESTMENT OFFICER | $1,942,627 |
| Earl A LeeMANAGING DIRECTOR, INVESTMENTS | $1,594,752 |
| Andrew LewisMANAGING DIRECTOR, INVESTMENTS | $1,401,714 |
| Eric KoehrsenMANAGING DIRECTOR, INVESTMENTS | $1,280,707 |
| Michael P Boyle MD CEO PRESIDENT & CEO | $1,275,151 |
Also paid on the latest return: Irena Barisic (EVP & CHIEF OPERATING & FINANCIAL OFFICER), $844,555; Gentiana S Arovas (MANAGING DIRECTOR, INVESTMENTS OPERATIONS), $819,659; John P Clancy MD (SVP, CLINICAL RESEARCH), $765,204; Albert Faro MD (Chief Medical Officer Beg. 7/1/2024), $671,590; STEVEn ROWE MD (EVP, Chief Scientific Officer), $667,206; Michael B Cavadel (SVP, CHIEF LEGAL OFFICER), $661,197; Enrique Lin Shiao PhD (Principal of Mission Related Investments), $589,642; Bruce Marshall MD (Chief Medical Officer Ending 7/1/2024), $550,128.
Also listed in Part VII of the latest return, with no pay reported: Carole B Griego MD (TRUSTEE), David A Mount (TREASURER), Dodzie Sogah PhD (TRUSTEE), Dominic J Caruso (TRUSTEE), Elise Eberwein (TRUSTEE), Eric R Olson PhD (VICE CHAIR), Eric Schneider MD (TRUSTEE), Jessica H Boyd MD (TRUSTEE), John S Weinberg (EXECUTIVE VICE CHAIR), Kate O'Donnell (TRUSTEE), Kc Bryan White (CHAIR), Louis A Defalco (VICE CHAIR), Paul A Motenko (TRUSTEE), Robert H Niehaus (VICE CHAIR), Steven Shak MD (TRUSTEE), Teresa L Elder (VICE CHAIR).
CEO pay by year
Each row is the CEO on that year's return.
| Fiscal year ending | Name and title | Total | Revenue | Source |
|---|---|---|---|---|
| Dec 2024 | Michael P Boyle MD CEO PRESIDENT & CEO | $1,275,151 | $355,798,320 | Filing |
| Dec 2023 | Michael P Boyle MD CEO PRESIDENT & CEO | $1,472,782 | $292,016,280 | Filing |
| Dec 2022 | Michael P Boyle MD CEO PRESIDENT & CEO | $1,349,782 | $248,630,352 | Filing |
How this pay was reported
The parts of each total, as reported on the return for the fiscal year ending December 2024.
Source: Form 990, fiscal year ending December 2024, IRS object ID 202533189349311948.View the filing
| Part VII | Schedule J | |||||||
|---|---|---|---|---|---|---|---|---|
| Name and title | From org | Other | Base | Bonus | Other | Deferred | Nontaxable | Total |
| John C Mahler Jr MDCHIEF INVESTMENT OFFICER | $1,866,868 | $75,759 | $766,301 | $1,091,398 | $9,169 | $34,656 | $41,103 | $1,942,627 |
| Earl A LeeMANAGING DIRECTOR, INVESTMENTS | $1,226,269 | $368,483 | $665,920 | $558,525 | $1,824 | $349,255 | $19,228 | $1,594,752 |
| Andrew LewisMANAGING DIRECTOR, INVESTMENTS | $1,363,454 | $38,260 | $469,402 | $891,950 | $2,102 | $20,856 | $17,404 | $1,401,714 |
| Eric KoehrsenMANAGING DIRECTOR, INVESTMENTS | $976,105 | $304,602 | $600,659 | $374,293 | $1,153 | $248,801 | $55,801 | $1,280,707 |
| Michael P Boyle MDPRESIDENT & CEO | $1,054,388 | $220,763 | $721,173 | $311,579 | $21,636 | $163,962 | $56,801 | $1,275,151 |
These figures come from Cystic Fibrosis Foundation's Form 990 returns, as the IRS publishes them. The methodology page explains how they're chosen. To report an error, email corrections@ceopaycheck.com.
How Cystic Fibrosis Foundation compares
Ranked 9th of 11 disease charities and medical research groups by CEO pay.
- Previous in this ranking: 8th, American Diabetes Association, $1,287,811
- Next in this ranking: 10th, Broad Institute, $982,376
Closest in revenue among organizations in the same revenue band:
NPR$697,251 (CEO), fiscal year ending Sep 2025
Association of American Medical Colleges$2,849,059 (CEO), fiscal year ending Jun 2025
United States Pharmacopeia$1,104,534 (CEO), fiscal year ending Jun 2025
San Francisco Foundation$670,879 (CEO), fiscal year ending Jun 2025
Blood Cancer United$930,517 (CEO), fiscal year ending Jun 2025
Common questions
Michael P Boyle MD (PRESIDENT & CEO) was paid $1,275,151 for the fiscal year ending December 2024: $1,054,388 from Cystic Fibrosis Foundation and $220,763 in other compensation (Part VII columns D and F).
The highest-paid person on the latest return was John C Mahler Jr MD (CHIEF INVESTMENT OFFICER), at $1,942,627. That is $667,476 more than the CEO, Michael P Boyle MD.
Cystic Fibrosis Foundation paid its CEO, Michael P Boyle MD, $1,275,151 for the fiscal year ending December 2024. That is down $197,631 (13.4%) from the fiscal year ending December 2023. The earliest return on record is for the fiscal year ending December 2022, when the CEO was Michael P Boyle MD, paid $1,349,782. By fiscal year end: December 2022, $1,349,782 (Michael P Boyle MD); December 2023, $1,472,782; December 2024, $1,275,151.
Cystic Fibrosis Foundation's return for the fiscal year ending December 2024 reports total expenses of $439,138,919 and total revenue of $355,798,320 (Part I, lines 18 and 12), so expenses exceeded revenue by $83,340,599. Expenses were $443,404,599 for the fiscal year ending December 2023, so they fell 1.0%. The CEO's pay of $1,275,151 equals 0.29% of expenses, our calculation.
From the 3 Form 990 returns Cystic Fibrosis Foundation filed with the IRS for fiscal years ending 2022 to 2024. The latest full-year return was filed on November 14, 2025. Schedule J of the fiscal year ending December 2024 return breaks down pay for all 5 people in the pay breakdown above.